Arthritis CD19+ B Cells

Arthritis CD19+ B Cells for Immunology Research

Arthritis CD19+ B Cells are cryopreserved from peripheral blood of IRB-consented adult donors diagnosed with arthritis. These CD19+ B cells reflect disease-associated immune alterations and support studies of B cell activation, humoral immunity, and — in seropositive donors — autoantibody production.

Which Type of Arthritis Do You Need?

B cell involvement varies sharply across the conditions grouped under “arthritis”, so the subtype determines whether these cells answer your question:

• Rheumatoid arthritis — the strongest B cell rationale. Local production of rheumatoid factor and anti-citrullinated protein antibodies (ACPA), and the reason B cell depletion is an established therapy
• Psoriatic arthritis — seronegative spondyloarthropathy; the B cell role is less central than in RA
• Osteoarthritis — degenerative, driven by cartilage breakdown rather than autoantibodies. B cells are of interest for low-grade synovial inflammation, not autoimmunity
• Gout — crystal-induced and innate-driven; B cells are largely bystanders
• Connective tissue disease — systemic lupus erythematosus and Sjögren’s syndrome, both markedly B cell–driven

If your protocol calls for a broad arthritis cohort rather than one diagnosis, we can assemble a mixed set with each donor’s subtype and serostatus annotated.

B Cells in Inflammatory Arthritis

• Autoantibody production in seropositive donors — rheumatoid factor and ACPA
• Expanded memory and plasmablast compartments during active disease
• Antigen presentation and T cell support, sustaining synovial inflammation
• Pro-inflammatory cytokine production and reduced regulatory B cell function
• Treatment effects — rituximab and other B cell–directed therapies reshape the compartment, so treatment status is essential context

Donor Stratification Available

• Arthritis subtype — specific diagnosis annotated per donor
• Serostatus — rheumatoid factor and anti-CCP positive or negative
• Disease activity — DAS28, CRP, ESR where recorded
• Treatment status — treatment-naive, conventional DMARD, biologic, or B cell–depleted
• Paired specimens — matched synovial fluid, serum, or PBMC from the same donor
• Matched healthy controls available

Product Features

• Research Use Only (RUO), CD19+ enriched B cells
• Isolated from clinically diagnosed arthritis donors
• High viability and enrichment
• Cryopreserved in CryoStor® CS10 media
• Processed within 24 hours of collection
• Flow cytometry purity and viability data per lot
• Ethically sourced with IRB approval and HIPAA compliance

De-identified Donor Data

• Confirmed diagnosis of arthritis, including subtype
• Demographics: age, sex assigned at birth, race/ethnicity
• Self-reported clinical history and medication use

Applications

• B cell phenotyping and function studies in arthritis
• Autoantibody production and BCR signalling studies
• BCR repertoire sequencing
• Comparative studies across arthritis subtypes
• B cell–depleting therapy mechanism research
• Disease mechanism studies and biomarker identification
• Preclinical immunotherapy development

Compliance and Quality Assurance

• IRB-approved collection and 21 CFR Part 11-compliant e-consent
• Standardized processing and quality protocols
• HIPAA-compliant data handling

Ordering & Customization

Arthritis CD19+ B Cells are offered in standard or custom aliquot sizes. For pricing, regulatory documentation, or international support, contact learnmore@sanguinebio.com. For the full range, see our human CD19+ B cells collection.